The contribution of Pseudomonas aeruginosa infection to clinical outcomes in bronchiectasis: a prospective cohort study

Rongchun Wang,Shuizi Ding,Cheng Lei,Danhui Yang,Hong Luo
DOI: https://doi.org/10.1080/07853890.2021.1900594
IF: 5.348
2021-01-01
Annals of Medicine
Abstract:<span>The impact of <i>Pseudomonas aeruginosa</i> on the prognosis of bronchiectasis remains controversial. This study aimed to explore the prognostic value of <i>P. aeruginosa</i> in adult patients with bronchiectasis in central-southern China.This prospective cohort study enrolled 1,234 patients with bronchiectasis between 2013 and 2019. The independent impact of <i>P. aeruginosa</i> on all-cause mortality, annual exacerbations, and hospitalizations was assessed.<i>P. aeruginosa</i> was isolated from 244 patients (19.8%). A total of 188 patients died over a follow-up period of 16 (1–36) months. Patients with <i>P. aeruginosa</i> had a longer disease course, poorer lung function, more lung lobe involvement, and more severe Bronchiectasis Severity Index (BSI) stage than those without <i>P. aeruginosa</i>. The independent impact of <i>P. aeruginosa</i> was observed on frequent hospitalizations but not on mortality and frequent exacerbations. Moderate- or high-risk comorbidities increased the risk of mortality (hazard ratio [HR]: 1.93, 95% confidence interval [CI]: 1.26–2.95), and this effect was magnified by the presence of <i>P. aeruginosa</i> (HR: 2.11, 95% CI: 1.28–3.48).<i>P. aeruginosa</i> infection acts as a marker of disease severity as well as predictor of frequent hospitalizations. <i>P. aeruginosa</i> had no independent effect on all-cause mortality. <i>P. aeruginosa</i> combined with moderate- or high-risk comorbidities posed an increased risk of mortality. The management of comorbidities may be a critical target during the treatment of <i>P. aeruginosa</i> infection in bronchiectasis.<i>P. aeruginosa</i> increased the risk of frequent hospitalizations; however, it had no independent impact on all-cause mortality.<i>P. aeruginosa</i> combined with moderate- or high-risk comorbidities posed an increased risk of mortality.The management of comorbidities may be a critical target during the treatment of <i>P. aeruginosa</i> infection in bronchiectasis.</span>
medicine, general & internal
What problem does this paper attempt to address?